Overactive Bladder - Results from #780

How can we better manage drug-resistant OAB/DO? ICI-RS 2018. December 16, 2019

Effects of the transobturator tape procedure on overactive bladder symptoms and quality of life: a prospective study. December 9, 2019

A preliminary study on the impact of detrusor overactivity on the efficacy of selective bladder denervation for the treatment of female refractory overactive bladder. December 8, 2019

Effect of an exercise programme for reducing abdominal fat on overactive bladder symptoms in young overweight women. December 1, 2019

Effects of biofeedback-based sleep improvement program on urinary symptoms and sleep patterns of elderly Korean women with overactive bladder syndrome. December 1, 2019

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). November 27, 2019

New targets for overactive bladder-ICI-RS 2109. November 25, 2019

Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. November 23, 2019

Evaluation of Choline and Acetylcholine Levels in Responders and Nonresponders to Anticholinergic Therapy for Overactive Bladder Syndrome. November 17, 2019

Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). November 16, 2019

Seasonal Variation of Overactive Bladder Symptoms in Female Patients. November 10, 2019

Overactive bladder symptoms in patients undergoing rigid and flexible cystoscopy. November 10, 2019

Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study. November 3, 2019

Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder (OAB). November 3, 2019

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. October 27, 2019

Development and Validation of a Machine Learning Algorithm for Predicting Response to Anticholinergic Medications for Overactive Bladder Syndrome. October 27, 2019

Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex. October 20, 2019

Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting. October 20, 2019

Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms-A Prospective Study. October 20, 2019

Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review. October 14, 2019

Page 40 of 122